INNOCAN PHARMA Corp
INNPF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $29 | $14 | $3 | $0 |
| % Growth | 115.5% | 433.7% | 1,205.6% | – |
| Cost of Goods Sold | $3 | $2 | $0 | $0 |
| Gross Profit | $26 | $12 | $2 | $0 |
| % Margin | 89% | 87.7% | 82.3% | 61.7% |
| R&D Expenses | $2 | $2 | $2 | $1 |
| G&A Expenses | $5 | $3 | $4 | $4 |
| SG&A Expenses | $26 | $14 | $7 | $6 |
| Sales & Mktg Exp. | $21 | $11 | $3 | $2 |
| Other Operating Expenses | $0 | -$8 | $0 | $0 |
| Operating Expenses | $27 | $8 | $8 | $8 |
| Operating Income | -$1 | $4 | -$6 | -$7 |
| % Margin | -4.2% | 27.8% | -244.9% | -3,816.3% |
| Other Income/Exp. Net | $2 | -$8 | $2 | -$3 |
| Pre-Tax Income | $1 | -$4 | -$4 | -$10 |
| Tax Expense | $1 | $0 | $0 | $0 |
| Net Income | -$2 | -$5 | -$4 | -$10 |
| % Margin | -6.2% | -34.4% | -147.1% | -5,126% |
| EPS | -0.42 | -1.19 | -0.982 | -2.906 |
| % Growth | 64.7% | -21.2% | 66.2% | – |
| EPS Diluted | -0.42 | -1.19 | -0.982 | -2.906 |
| Weighted Avg Shares Out | 4 | 4 | 4 | 3 |
| Weighted Avg Shares Out Dil | 4 | 4 | 4 | 3 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$1 | -$4 | -$4 | -$7 |
| % Margin | -4.1% | -27.6% | -144.5% | -3,761% |